BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abstral fentanyl regulatory update

Paladin said Health Canada approved Abstral fentanyl to treat breakthrough pain in patients receiving opioid analgesics for underlying chronic cancer pain. The company plans to launch...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >